Miriam-Rose Menezes Ph.D. Email & Phone Number

Philadelphia, Pa, Us

In my role, I craft strategies for the design and execution of pre-clinical studies, driving the advancement of gene therapy candidates. I collaborate with cross-functional teams to evaluate and optimize vector constructs for enhanced therapeutic efficacy. I also direct the planning and implementation of in-vitro and in-vivo experiments to assess vector performance and safety. By spearheading the analysis and interpretation of complex data sets, I facilitate evidence-based decision-making processes. Additionally, I innovate methodologies to streamline experimental workflows and improve research efficiency. My collaborative efforts ensure the integration of scientific findings and methodologies into project management and execution, aligning with organizational goals.Below are a few of my notable contributions:• Designed and implemented automated plasmid DNA production platforms to meet pipeline demands and enhance product and process development.• Reduced process bottlenecks by 60% through development and transfer of nanoplate-based HT-dPCR for Vg titer, enhancing in-process testing.• Published two articles in peer-reviewed journals, contributing to the scientific community and enhancing personal and organizational reputation.• Delivered oral presentations at two international conferences, showcasing research findings and fostering industry collaboration.• Led and mentored interns as well as co-op students in high-throughput screening projects to optimize adeno-associated virus (AAV) production, refining existing processes.

New York, Ny, Us

In my role, I facilitated collaborations with external institutes to optimize hit molecules for SAR and hit-to-lead conversion. I provided expertise and training to researchers on advanced techniques such as SPR (Biacore), DSF, MST/HT-MST, and DLS for hit validation. As a subject matter expert, I contributed to the development of cell-based assays and the utilization of the Molecular Devices IXM-XL high-content screening platform. I established and maintained protocols to ensure efficient and accurate hit validation and lead optimization processes. Leveraging my expertise in molecular biology and assay development, I drove innovation and efficiency in research projects while adhering to strict quality standards and regulatory guidelines in all experimental procedures.Below are a few of my notable contributions:• Designed, developed, and implemented high-throughput screening (HTS) of 400,000 small molecules using biochemical assays to propel oncology, COVID-19, and cardiovascular therapeutic discovery.• Facilitated transition of hit molecules into lead optimization phase through effective collaboration and partnership with external research entities.• Enhanced research capabilities by training fellow researchers in advanced validation techniques, significantly improving project throughput and accuracy.

Houston, Texas, Us

I initiated and spearheaded a collaborative effort with GSK to validate hits and optimize leads, paving the way for potential therapeutic advancements. I managed and curated CRISPR-Cas9 engineered cell lines and maintained a mouse colony to investigate the role of microRNAs in breast cancer pathogenesis. Actively engaging in scientific discourse, I contributed novel insights to the fields of oncology and molecular biology. I implemented rigorous experimental protocols and methodologies to ensure the reliability and reproducibility of research outcomes. Additionally, I fostered a collaborative and inclusive research environment, facilitating interdisciplinary exchange and knowledge sharing.Below are a few of my notable contributions:• Established a partnership with GSK, leading to pre-DePac collaboration for hit validation and lead optimization.• Authored four peer-reviewed articles, contributing to scientific community's understanding of targeted cancer therapies.• Presented research findings at three international conferences, showcasing expertise in cell-based assay development and molecular biology.

Worked in a team of six to : Provide consultancy services to strategize market entry for TMC Biotech Startups.Wrote patent drafts to protect IP for early stage TMC Biotech companies.

Houston, Texas, Us

This internship provided me with the opportunity to gain insights into commercialization of life science technologies. I performed due diligence to determine feasibility of assets from pharmaceutical companies for further studies. I worked with one of the portfolio companies to determine the feasibility of repurposing a therapeutic compound for a novel application and assisted with writing of SBIR-Phase II grants.

New Haven, Ct, Us

I conducted cutting-edge research using genetically engineered mouse models and cell culture systems to elucidate the mechanisms of tumorigenesis linked to patient-associated variants of DNA repair proteins. By employing molecular cloning techniques, I created precise genetic modifications in mice, advancing our understanding of germline DNA repair protein variants in cancer development. Leveraging advanced epifluorescent and confocal microscopy, I investigated the role of base-excision repair during meiosis, contributing significantly to the field of reproductive biology. Additionally, I spearheaded the development of targeting constructs to elucidate the genetic underpinnings of tumorigenesis, thereby enhancing the lab's research capabilities.Below are a few of my notable contributions:• Authored three peer-reviewed publications, showcasing findings on base-excision repair protein variants and role in cancer.• Presented research findings at multiple international conferences, highlighting lab's contributions to scientific community.• Provided mentorship and hands-on training to junior researchers, ensuring rigorous scientific inquiry and project fidelity.

Omaha, Nebraska, Us

I managed multi-departmental collaborations to demonstrate the mechanism by which the nucleotide pool cleansing enzyme, Inosine triphosphate pyrophosphates (ITPA) contributed to increased mutagenesis as well as adverse drug reactions in patients administered with base analogs as part of an immune-suppressive regimen.

Doctor Of Philosophy (Ph.D.), Cancer Research

Master Of Science (M.Sc.), Biophysics

Bachelor Of Science (B.Sc.), Microbiology And Biotechnology